Saving the pneumococcal AMC and GAVI

Abstract

The GAVI Alliance, a key institution in saving poor children by increasing the use of vaccines, is mounting a campaign in early 2011 to raise $4.1 billion to close its funding crisis. Yet much of this shortfall stems from its own decisions, especially around the Advance Market Commitment (AMC), a costly kind of surplus contract GAVI is using to save poor children by selling new, global pneumococcal conjugate vaccines (PCVs) at deep discount. This essay explains how the AMC became a surplus contract, why it and GAVI are in financial straits and how to save both. It concludes with thoughts about how generous and caring donors can maximize the number of children saved.

Commentaries to this article: http://www.landesbioscience.com/journals/vaccines/article/15218/

http://www.landesbioscience.com/journals/vaccines/article/15217/

http://www.landesbioscience.com/journals/vaccines/article/15361/

http://www.landesbioscience.com/journals/vaccines/article/15360/

http://www.landesbioscience.com/journals/vaccines/article/15359/

http://www.landesbioscience.com/journals/vaccines/article/15215/

http://www.landesbioscience.com/journals/vaccines/article/15216/

http://www.landesbioscience.com/journals/vaccines/article/15357/

http://www.landesbioscience.com/journals/vaccines/article/15355/